Abstracts tagged "Biologicals"

Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Frank Behrens¹, Patrizia Sternad², Klaus Krueger³, Christine App⁴, Stephanie Lefevre⁴ and Christiane Schiedel⁴, ¹Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ²Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ³Rheumatologisches Praxiszentrum, München, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…
Abstract Number: LB09 • ACR Convergence 2025
Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis
Elisa Dalix¹, Philippe Goupille², Daniel Wendling³, Christian Roux⁴, Jean-Hughes Samon⁵, Olivier Brocq⁶, Anne Tournadre⁷, Arnaud Constantin⁸, Maxime Breban⁹, Gregoire Cormier¹⁰, Tristan Pascart¹¹, Thierry Lequerre¹², Pascal Claudepierre¹³, Eric Lespessailles¹⁴, Benoit Legoff¹⁵, Jeremie Sellam¹⁶, Athan Baillet¹⁷, Thierry Schaeverbeke¹⁸, Stephan Pavy¹⁹, Valerie Devauchelle-Pensec²⁰, Elisabeth Gervais²¹, Laure Gossec²², Corinne Miceli²³, Yves-Marie Pers²⁴, Cedric Lukas²⁵, Renaud Felten²⁶, Beatrice Bouvard²⁷, Amelie Denis²⁸, Emmanuelle Dernis²⁸, Emilie Presles²⁹, Florence Rancon²⁹ and Hubert Marotte³⁰, ¹Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM, Saint-Etienne, France, ²Department of Rheumatology and INSERM-CIC¹⁴¹⁵, University Hospital of Tours, EA ⁷⁵⁰¹ GICC, University of Tours, Tours, France, ³Rhumatologie, CHU de Besançon, Besancon, France, ⁴Service de rhumatologie, CHU de Nice, IbV, Université Cote d'Azur, Nice, France, ⁵Service de Rhumatologie, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims, Reims, France; Université de Reims Champagne-Ardenne, Faculté de Médicine, EA ³⁷⁹⁷, Reims, France, ⁶Rheumatology Department, CHPG Monaco, Monaco, Monaco, ⁷Rheumatology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁸Rheumatology Center, Toulouse University Hospital, Toulouse, France, ⁹INSERM UMR¹¹⁷³, INFLAMEX, Laboratoire d'Excellence, Rheumatology Division, Ambroise Paré Hospital (AP-HP), Paris, France, ¹⁰Rheumatology, Centre Hospitalier Departemental Vendee, La Roche-sur-Yon, France, ¹¹Department of Rheumatology, Université Catholique de Lille Hôpital Saint Philibert, Lomme, France, ¹²Department of Rheumatology & CIC-CRB ¹⁴⁰⁴, Inserm, PANTHER UMR ¹²³⁴, University of Rouen Normandie, Normandie University, CHU Rouen, Rouen, France, ¹³AP-HP, Henri-Mondor Hospital, Department of Rheumatology, EpiDermE, Université Paris Est Créteil, Créteil, France, ¹⁴Translational Medicine Research Platform, PRIMMO, University Hospital Centre of Orleans, Orleans, France, ¹⁵Nantes Université, ONIRIS, Univ Angers, CHU Nantes, INSERM, Regenerative Medicine and Skeleton, RMeS, UMR ¹²²⁹, Nantes, France, ¹⁶Rheumatology Department, Sorbonne Université, Saint-Antoine Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Centre de Recherche Saint-Antoine (CRSA) Inserm UMRS-⁹³⁸,, Paris, France, ¹⁷Université Grenoble Alpes, ⁴UMR⁵⁵²⁵, Grenoble, France, ¹⁸Department of Rheumatology, Hôpital Pellegrin, Bordeaux, France, ¹⁹Department of Rheumatology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicetre, ²⁰Department of Rheumatology, Université de Bretagne Occidentale, CHU Brest, INSERM (U¹²²⁷), LabEx IGO, Brest, France, ²¹LITEC, Université de Poitiers, CHU Poitiers, Poitiers, France, ²²Sorbonne Université, AP-HP & EULAR, Paris, France, ²³Immunoregulation Unit, Institut Pasteur, Cochin AP-HP, Paris, France, ²⁴IRMB, University of Montpellier, Inserm U¹¹⁸³, CHU Montpellier, Montpellier, France, ²⁵Rheumatology department, CHU and University of Montpellier, Montpellier, France; UMR UA¹¹ Inserm (IDESP), University of Montpellier, Montpellier, France, ²⁶Service de Rhumatologie, CHU de Strasbourg - Hôpital de Hautepierre, Strasbourg, France, ²⁷Rhumatologie, Centre Hospitalier Universitaire, Angers, France, ²⁸CH Le Mans, Le Mans, France, ²⁹CHU Saint-Etienne, CIC ¹⁴⁰⁸, Saint-Etienne, France, ³⁰Université Jean Monnet, CHU de Saint-Etienne, CIC ¹⁴⁰⁸, Mines Saint-Etienne, INSERM, SSINBIOSE ¹⁰⁵⁹, Saint-Etienne, France
Background/Purpose: Axial spondyloarthritis (axSpA) is initially treated with non-steroidal anti-inflammatory drugs. In case of inadequate response, ACR/EULAR recommend biological disease-modifying antirheumatic drugs (bDMARDs). Up to…
Abstract Number: LB11 • ACR Convergence 2025
Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
Dong Xu¹, Shangzhu Zhang¹, Lin Qiao¹, Li Zhang¹, Wenxiang Wang², Lin Li², Binghua Xiao², Jing Zhang², Qing Zuraw³, Jianmin Fang² and Xiaofeng Zeng¹, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China (People's Republic), ²RemeGen Co., Ltd., Rheumatology, Yantai, China (People's Republic), ³Vor Biopharma Inc., Boston
Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease whose pathogenesis is associated with aberrant activation of B-lymphocytes. Telitacicept, a novel fusion protein, dually targets and…
Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
David Silverman¹, Timothy Barnes², Nnaemeka Odo², Jared Silver³, Lisa Le², Amy Edgecomb⁴ and Hitesh Patel⁵, ¹Rheumatology Department, Kaiser Permanente Colorado Medical Group, Denver, Colorado, ²Value and Evidence Solutions, Optum Life Sciences, Eden Prairie, Minnesota, ³Clinical Development, Amgen, Thousand Oaks, California, ⁴Anti-infectives and Respiratory, GSK, Philadelphia, Pennsylvania, ⁵US Medical Affairs, GSK, Durham, North Carolina
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…
Abstract Number: 0011 • ACR Convergence 2025
KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release
Min Bao, John Wang, Jay Zhao and Weihao Xu, Kali Therapeutics, San Mateo, CA
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis…
Abstract Number: 0473 • ACR Convergence 2025
A Phase 2b Dose-Ranging Study of Peresolimab for Adults with RA
Jay Tuttle¹, Kirstin Griffing², Mark Genovese², Hyungmin Rha², So Young Park², Pia Yachi¹, Ajay Nirula¹, LANCE PFEIFER², Tami Jo Rayle², Jesus Abraham Simón-Campos³, Clifton Bingham⁴, Kevin Winthrop⁵, Daniel Aletaha⁶, Iain McInnes⁷, Yu Xue⁸, Yoshiya Tanaka⁹, Roy Fleischmann¹⁰, Paul Emery¹¹ and Michael Weinblatt¹², ¹Lilly Biotechnology Center, San Diego, CA, ²Eli Lilly and Company, Indianapolis, IN, ³Köhler & Milstein Research, UADY School of Medicine, Merida, Yucatan, Mexico, ⁴Johns Hopkins University, Baltimore, MD, ⁵Oregon Health & Science University, Portland, OR, ⁶Medical University Vienna, Wien, Austria, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ⁹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Peresolimab, a humanized IgG1 mAb, activates programmed cell death protein 1. In a phase 2a study, peresolimab demonstrated efficacy in participants (pts) with RA…
Abstract Number: 0760 • ACR Convergence 2025
The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis
Sema Kaymaz-Tahra¹, Cansu Arslantürk Güneysu², Sinem Nihal Esatoglu³, Güllü Sandal Uzun⁴, Burak Ince⁵, Mete Kara⁶ and Gulen Hatemi³, ¹Bahcesehir University Faculty of Medicine Department of Internal Medicine Division of Rheumatology, Istanbul, Turkey, ²Sakarya Training and Research Hospital, Division of Rheumatology, Sakarya, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Hacettepe University, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁵Istanbul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, ⁶Izmir City Hospital, Division of Rheumatology, Izmir
Background/Purpose: To assess the sustained remission rates of the targeted therapies in 52th week in patients with giant cell arteritis (GCA).Methods: We performed a systematic…
Abstract Number: 0571 • ACR Convergence 2025
Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
Jaejoon Lee¹, A-Hyun Cho², Yu Jin Kim², Seulkee Lee³, Seonyoung Kang⁴, Hyungjin Kim⁵, Hoon-Suk Cha¹ and Hong-Hee Won², ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea, ³Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea, ⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Biologics have transformed the management of axial spondyloarthritis (axSpA). Currently, it is challenging to identify patients who would benefit from early biologics, resulting in…
Abstract Number: 1042 • ACR Convergence 2025
Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after
Eric Roberts¹, gabriela Schmajuk², Diana Ung³, Mackenzie Clark³ and Jinoos Yazdany⁴, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, ⁴UCSF, San Francisco, CA
Background/Purpose: In 2023 patent exclusivity for adalimumab expired and nine biosimilars were introduced to the U.S. market with a tenth launched in May 2024. The…
Abstract Number: 1179 • ACR Convergence 2025
Efficacy and Safety of Ruxolitinib in Adult Patients With Refractory Connective Tissue Disease-Associated Macrophage Activation Syndrome
Jingjing Li¹, Ran Wang¹, Jie Chen¹, Antao xu¹, Yakai Fu¹, Yanwei Lin¹, Xiaodong Wang¹, Shuang Ye², Fang Du¹ and Qiong Fu³, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ²Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ³Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: Macrophage activation syndrome (MAS) is a rare and life-threatening complication of connective tissue diseases (CTDs), with approximately 30% of cases being refractory to standard…
Abstract Number: 1427 • ACR Convergence 2025
Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
Rebeca L. Polina-Lugo¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Esteban C. Garza-Gonzalez⁴, Ricardo I. De la Rosa-Vazquez⁵, Victoria P. Limas-Martínez⁵, Annette Dominguez-Guerra⁵, Jesus Alberto Cardenas-de la Garza⁶, Iris J. Colunga-Pedraza³, Dionicio A. Galarza-Delgado³, Jose R Azpiri-Lopez⁷, Victor M Fraga-Enriquez⁸ and Diego Azamat Salcedo Almanza⁹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolas de los Garza, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁸Cardiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ⁹Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Patients with psoriatic arthritis (PsA) have an increased cardiovascular (CV) risk due to a higher prevalence of comorbidities and chronic systemic inflammation. In those…
Abstract Number: 1531 • ACR Convergence 2025
Achieving Remission and Low Disease Activity with Belimumab Versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Ioannis Parodis¹, Julius Lindblom², Roger A. Levy³, Alexander Tsoi¹, Margherita Zen⁴, Dionysis Nikolopoulos⁵, Munther Khamashta⁶, Ryan Tomlinson⁷, Anca Askanase⁸, Ronald van Vollenhoven⁹ and Mandana Nikpour¹⁰, ¹Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁴University of Padua, Department of Medicine, Division of Rheumatology, Padua, Italy, ⁵Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁶GSK, Medical Affairs, Dubai, United Arab Emirates, ⁷GSK, Development – R&D, Collegeville, PA, ⁸Columbia University Medical Center, New York, NY, ⁹Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹⁰University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia
Background/Purpose: An integrated post hoc analysis of five Phase 3 trials in adults with SLE showed greater benefit of belimumab (BEL) than placebo (PBO), plus…
Abstract Number: 1766 • ACR Convergence 2025
Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study
caterina ricordi¹, Maxime Beydon², Johanne Liberatore³, Pascal Cohen⁴, bertrand Dunogue⁵, Camille Mettler⁶, Benjamin Torreau⁷, Luc Mouthon⁵, Xavier Puéchal⁸ and Benjamin Terrier⁹, ¹Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²Sorbonne University, INSERM, Institut Pierre Louis of Epidemiology and Public Health, Equipe PEPITES, Pitié Salpêtrière Hospital, Service of Public Health, Centre of Pharmacoepidemiology (Cephepi), Paris, France, ³Department of Internal Medicine, Centre Hospitalier d’Angouleme, Angouleme, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁶Department of Internal Medicine, Hôpital Bichat - Claude-Bernard, Paris, France, ⁷Internal Medicine and Immunology, CHU Tours, Tours, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁹Cochin Hospital, Paris, France
Background/Purpose: Rituximab (RTX) is the standard of care for both induction and maintenance in ANCA-associated vasculitides (AAVs). While CD19 B-cell monitoring is used to evaluate…
Abstract Number: 2271 • ACR Convergence 2025
Assessing the Real-World Impact of Earlier Initiation of Adalimumab vs. Conventional Synthetic DMARDs on Healthcare Resource Utilization in Patients with Rheumatoid Arthritis in Europe
Daniel Aletaha¹, Dr. Carmen Bremer², Jack Milligan³, Zichun Cao⁴, Rachael Meadows³ and Xenofon Baraliakos⁵, ¹Medical University Vienna, Wien, Austria, ²Sandoz International GmbH, Holzkirchen, Germany, ³Adelphi Real World, Macclesfield, United Kingdom, ⁴Sandoz Incorporated, Princeton, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Early use of targeted therapy (TT), such as anti-tumor necrosis factor (anti-TNF) biologics, show improved outcomes for RA1, but costs often limit access. Biosimilars,…
Abstract Number: 2369 • ACR Convergence 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
Philip J. Mease¹, Jessica A. Walsh², Timothy P. Fitzgerald³, Soumya Chakravarty⁴, Elizabeth Adamson⁵, Bruno Emond⁶, Carmine Rossi⁷, Samuel Schwartzbein⁷, Kana Yokoji⁷, Yuxi Wang⁷, Patrick Lefebvre⁷, Dominic Pilon⁷, Shikha Singla⁸ and Joseph F Merola⁹, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ³Johnson & Johnson, Horsham, PA, USA, PA, ⁴Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁵Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁶Analysis Group, Inc., Montreal, QC, Canada, QC, ⁷Analysis Group, Inc., Montreal, QC, Canada, QC, Canada, ⁸Medical College of Wisconsin, Milwaukee, WI, ⁹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Prior research reported that patients (pts) with psoriatic arthritis (PsA) treated with guselkumab (GUS) were 1.5x more likely to remain persistent with on-label treatment…

1
2
3
…
67
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].